Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: KTTAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pasithea Therapeutics Corp. filings document the formal reporting record for a clinical-stage biotechnology company with common stock and warrants registered on The Nasdaq Capital Market. The disclosures cover PAS-004-related corporate context, security classes, emerging growth company status, and material events reported on Form 8-K.
Recent regulatory filings include Nasdaq listing-compliance notices, executive officer appointments tied to clinical development leadership, and proxy materials for annual meeting matters. The proxy record addresses director elections, auditor ratification, equity compensation plan amendments, and capital-structure proposals, while 8-K filings report governance changes and other current events affecting the issuer and its listed securities.
Pasithea Therapeutics reporting persons CVI Investments, Inc. and Heights Capital Management, Inc. disclose beneficial ownership of 826,145 shares of common stock through Series C and Series D warrants, representing 9.9% of the outstanding class. The Warrants include a contractual limitation that prevents exercise to the extent such exercise would raise ownership above 9.99%. Heights Capital, as investment manager to CVI Investments, may be deemed to have shared voting and dispositive power over the reported position, while neither reporting person claims sole voting or dispositive power. The filing also references 7,443,577 shares outstanding (excluding shares underlying the warrants) as reported in the company's quarterly report.
Pasithea Therapeutics (Nasdaq:KTTA) filed an 8-K reporting receipt of a Nasdaq bid-price deficiency notice on 23-Jun-2025. The company’s shares traded below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5550(a)(2). Pasithea has 180 days—until 22-Dec-2025—to regain compliance by posting a closing bid of at least $1.00 for 10 straight sessions. A second 180-day extension is possible if other listing standards are met and the firm commits to a remedy such as a reverse split. There is no immediate delisting; business operations and SEC reporting remain unaffected. Management is monitoring share price and evaluating options to restore compliance.